"Conditional approval" draws dissent

Share this article:

Could new drugs be less expensively and more rapidly brought to market if premarket clinical trials for proof of effectiveness were scaled back?

That has been the drumbeat from former FDA commissioner Andrew von Eschenbach, but former Pfizer R&D president John LaMattina disagrees.

In a Forbes online post, LaMattina said that the proposal would save money and get drugs to market faster, but at a cost of increased safety risks.

Now head of the Manhattan Institute's Project FDA initiative, von Eschenbach insists that reducing Phase 3 requirements “would be particularly effective for some chronic diseases.”

But LaMattina, who is also a senior partner at PureTech Ventures, writes that this “would likely result in more drug recalls and more liability costs.”

Phase 3 trials are needed to understand a drug's risk/benefit profile before it hits the market, LaMattina says. “The FDA does a good job in evaluating the risks and benefits for new drugs under the current paradigm,” he ­concludes.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.